Please note, this OEL/ADE monograph also applies to naftidrofuryl oxalate (CAS RN 3200-06-4), naftidrofuryl citrate (CAS RN 85293-34-1), and naftidrofuryl fumarate (CAS RN 3200-07-5). Naftidrofuryl, also known as nafronyl, is used as a vasodilator in the treatment of peripheral and cerebral vascular disorders, including manifestations such as painful symptoms of arteritis, intermittent claudication, night cramps, and rest pain. Additionally, it has established clinical utility in managing Raynaud's syndrome, incipient gangrene, trophic ulcers, diabetic arteriopathy, and acrocyanosis. It is also claimed to enhance cellular oxidative capacity thereby protecting cells against the results of ischemia.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Naftidrofuryl, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.